Kidney Cancer Gets A Double Uplift From Latest CHMP Meeting

During its July 2016 meeting, the EU's top scientific advisory panel, the Committee for Medicinal Products for Human Use, recommended approval for two anticancers, cabozantinib and lenvatinib, that will likely shake up the advanced kidney cancer sector, and a new therapy for pancreatic cancer, liposomal and pegylated irinotecan.

Thumbs Up

The EU's CHMP has recommended approval for two new drugs for the treatment of advanced renal cell carcinoma, Ipsen's Cabometyx (cabozantinib) and Eisai Europe Ltd.'s Kisplyx (lenvatinib), adding to the number of options available to doctors to treat the condition, and the complexity of a sector that will likely soon include generic versions of its leading products as well as novel kinase and checkpoint inhibitors.

Cabometyx and Kisplyx were recommended for the treatment of adult patients with advanced renal cell carcinoma previously treated with a...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from New Products

More from Scrip